Friday, Oct 09th

Last update03:31:45 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.


Most Recent Related Stories...

Obama signs bill preventing healthcare cost increase

ObamaPresident Obama signed changes into Obamacare preventing health insurance premium increases for millions.The rare bipartisan changes,...

California governor signs assisted suicide bill

California assisted suicide bill signedCalifornia will become the fifth state to allow terminally ill patients to legally end their lives...

FDA approves new treatment for advanced lung cancer

new lung cancer drugThe Food and Drug Administration approved a new drug for patients with advanced non-small cell lung...

Scientists share Nobel Prize for medicine for anti-parasite drugs

Nobel in medicineThree scientists from Japan, China and Ireland whose discoveries led to the development of potent new...
America's # 1 Enemy
Tee Shirt
& Help Support!
TVNL Tee Shirt
Conserve our Planet
& Help Support!
Get your 9/11 & Media
Deception Dollars
& Help Support!
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!